Arbutus Biopharma

456 articles about Arbutus Biopharma

• Tekmira Pharmaceuticals Corporation Announces Second Quarter 2009 Operating Results and Provides Corporate Update

  8/12/2009

• Tekmira Pharmaceuticals Corporation Conference Call Advisory; Second Quarter 2009 Operating Results and Corporate Update

  8/7/2009

• Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation Participate in New Research Collaboration

  8/6/2009

• Tekmira Pharmaceuticals Corporation Initiates ApoB SNALP Phase 1 Clinical Trial

  7/6/2009

• Tekmira Pharmaceuticals Corporation Presents ApoB SNALP and PLK1 SNALP Data at Leading Scientific Conference

  5/28/2009

• Strong Immune Response To New siRNA Drugs In Development May Cause Toxic Side Effects, Tekmira Pharmaceuticals Corporation Study

  5/20/2009

• Tekmira Pharmaceuticals Corporation Announces First Quarter 2009 Operating Results and Provides Corporate Update

  5/13/2009

• Tekmira Pharmaceuticals Corporation Conference Call Advisory; First Quarter 2009 Operating Results and Corporate Update

  5/11/2009

• Tekmira Pharmaceuticals Corporation Receives Clearance From FDA to Initiate ApoB SNALP Phase 1 Clinical Trial

  5/7/2009

• Tekmira Pharmaceuticals Corporation Files IND for ApoB SNALP

  4/14/2009

• Tekmira Pharmaceuticals Corporation Partner Alnylam Pharmaceuticals Initiates ALN-VSP Phase 1 Trial in Patients With Liver Cancer

  4/3/2009

• Tekmira Pharmaceuticals Corporation Reports 2008 Audited Results and Provides Corporate Update

  3/24/2009

• Tekmira Pharmaceuticals Corporation Call Advisory 2008 Audited Results and Corporate Update

  3/19/2009

• Tekmira Pharmaceuticals Corporation Presents Data Demonstrating Further Increases in SNALP Potency

  2/24/2009

• Tekmira Pharmaceuticals Corporation Partner Alnylam Pharmaceuticals Presents Data on Programs Using Tekmira's SNALP Technology at Keystone Meeting

  2/12/2009

• Tekmira Pharmaceuticals Corporation Partner Alnylam Pharmaceuticals Receives Clearance From FDA to Initiate Clinical Trial Utilizing SNALP

  1/23/2009

• Tekmira Pharmaceuticals Corporation Announces $11.2 Million 3-Year Manufacturing and Development Commitment From Partner Alnylam Pharmaceuticals

  1/8/2009

• Tekmira Pharmaceuticals Corporation Partner Alnylam Pharmaceuticals Files First IND for an RNAi Therapeutic Utilizing SNALP

  12/23/2008

• Tekmira Pharmaceuticals Corporation Announces Third Quarter 2008 Operating Results and Provides Program Update

  11/13/2008

• Tekmira Pharmaceuticals Corporation Announces Presentation of Data Using SNALP RNAi Delivery Technology

  10/22/2008